Umbilical cord mesenchymal stem cells promote angiogenesis of ischemic lower limbs

doi:10.3969/j.issn.2095-4344.2015.36.025

Abstract

Abstract:

BACKGROUND: Under certain conditions, stem cells can be induced to differentiate into vascular endothelial cells, which can promote the angiogenesis of ischemic lower limbs and the establishment of effective circulation and improve distal blood supply of the ischemic limbs.

OBJECTIVE: To review the biological characteristics and pro-angiogenesis mechanism of umbilical cord mesenchymal stem cells and to investigate the current status of umbilical cord mesenchymal stem cells in the repair of neuropathy and chronic wounds.

METHODS: PubMed, VIP and Wanfang databases were searched for relevant articles published from 2000 to 2015 using the keywords of “stem cells transplantation, umbilical cord mesenchymal stem cell, diabetic angiopathies” in English and Chinese, respectively.

RESULTS AND CONCLUSION: Compared with peripheral blood stem cells and bone marrow mesenchymal stem cells, umbilical cord mesenchymal stem cells are characterized as more widespread sources, easy collection, stronger amplification ability, no immunogenicity, and no ethical controversy, which have become ideal target and seed cells for pro-angiogenesis and gene therapy in ischemic diseases. Umbilical cord mesenchymal stem cells can differentiate into vascular endothelial cells and fibroblasts involved in wound healing. In addition, these cells can promote the production and expression of neurotrophic factors, promote nerve regeneration in ischemic tissues, and participate in tissue repair and accelerate healing of ulcers by paracrine and autocrine cytokines, anti-inflammation and immunomodulation. Therefore, umbilical cord mesenchymal stem cells have a broad prospect in the improvement of diabetic lower limb ischemia, repair of diabetic peripheral neuropathy and promotion of chronic ulcer healing. Compared with stem cell transplantation alone, umbilical cord mesenchymal stem cells transplantation combined with gene therapy can further enhance cell survival and pro-angiogenesis.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Umbilical Cord, Mesenchymal Stem Cells, Diabetes Mellitus

CLC Number:

R318

Li Xiao-ling, Zhu Lv-yun, Song Guang-yao. Umbilical cord mesenchymal stem cells promote angiogenesis of ischemic lower limbs[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(36): 5878-5885.

Figures/Tables 1

References

[1] Wang A, Xu Z, Mu Y, et al. Clinical characteristics and medical costs in patients with diabetic amputation and nondiabetic patients with nonacute amputation in central urban hospitals in China. Int J Low Extrem Wounds. 2014; 13(1):17-21.

[2] Bruun C, Siersma V, Guassora AD, et al. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity. Diabet Med. 2013;30(8):964-972.

[3] Leone S, Pascale R, Vitale M, et al. Epidemiology of diabetic foot. Infez Med. 2012;20 Suppl 1:8-13.

[4] Becker F, Robert-Ebadi H, Ricco JB, et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011;42 Suppl 2:S4-12.

[5] Holman N, Young RJ, Jeffcoate WJ. Variation in the recorded incidence of amputation of the lower limb in England. Diabetologia. 2012;55(7):1919-1925.

[6] Witsø E, Lium A, Langeng E, et al. Diabetic foot team and incidence of amputations. Tidsskr Nor Laegeforen. 2011; 131(8):804-805.

[7] Vamos EP, Bottle A, Edmonds ME, et al. Changes in the incidence of lower extremity amputations in individuals with and without diabetes in England between 2004 and 2008. Diabetes Care. 2010;33(12):2592-2597.

[8] Lobo R, Kiernan TJ, Jaff MR. Medical therapy for critical limb ischemia and the diabetic foot: an update. J Cardiovasc Surg (Torino). 2013;54(6):671-678.

[9] Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012;61(11):2937-2947.

[10] McEwen LN, Ylitalo KR, Herman WH, et al. Prevalence and risk factors for diabetes-related foot complications in Translating Research Into Action for Diabetes (TRIAD). J Diabetes Complications. 2013;27(6):588-592.

[11] Schaper NC, Apelqvist J, Bakker K. Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia. 2012; 55(7):1869-1872.

[12] Jørgensen ME, Almdal TP, Faerch K. Reduced incidence of lower-extremity amputations in a Danish diabetes population from 2000 to 2011. Diabet Med. 2014;31(4):443-447.

[13] Malone M, White JM, Taylor L, et al. Update on the inaugural Sydney Diabetic Foot Conference 2013. Int J Low Extrem Wounds. 2013;12(3):242-244.

[14] Ramachandran A, Lakshmi S, Arun N, et al. Role of industries in the care of diabetic foot. Int J Low Extrem Wounds. 2010; 9(3):116-121.

[15] Dash SN, Dash NR, Guru B, et al. Towards reaching the target: clinical application of mesenchymal stem cells for diabetic foot ulcers. Rejuvenation Res. 2014;17(1):40-53.

[16] Mohammadzadeh L, Samedanifard SH, Keshavarzi A, et al. Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Exp Clin Endocrinol Diabetes. 2013;121(1): 48-53.

[17] Jackson WM, Nesti LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells. Stem Cells Transl Med. 2012;1(1): 44-50.

[18] Keats EC, Khan ZA. Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise. Cardiovasc Diabetol. 2012;11:37.

[19] Mulder GD, Lee DK, Jeppesen NS. Comprehensive review of the clinical application of autologous mesenchymal stem cells in the treatment of chronic wounds and diabetic bone healing. Int Wound J. 2012c;9(6):595-600.

[20] Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92(1):26-36.

[21] Watson N, Divers R, Kedar R, et al. Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy. 2015;17(1):18-24.

[22] 李晓玲,朱旅云,赵芳.脐带Wharton's Jelly中间充质干细胞的生物学特性[J].中国组织工程研究与临床康复,2011,15(32): 5979-5982.

[23] De Bruyn C, Najar M, Raicevic G, et al. A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. Stem Cells Dev. 2011;20(3):547-557.

[24] Ben Azouna N, Jenhani F, Regaya Z, et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther. 2012;3(1):6.

[25] Phillips JE, Petrie TA, Creighton FP, et al. Human mesenchymal stem cell differentiation on self-assembled monolayers presenting different surface chemistries. Acta Biomater. 2010;6(1):12-20.

[26] Al-Nbaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013;9(1): 32-43.

[27] Deuse T, Stubbendorff M, Tang-Quan K, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011;20(5):655-667.

[28] Mauro A, Buscemi M, Gerbino A. Immunohistochemical and transcriptional expression of matrix metalloproteinases in full-term human umbilical cord and human umbilical vein endothelial cells. J Mol Histol. 2010;41(6):367-377.

[29] Neef K, Choi YH, Weichel A, et al. The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness. Cytotherapy. 2012;14(6):670-678.

[30] Bernardi S, Severini GM, Zauli G, et al. Cell-based therapies for diabetic complications. Exp Diabetes Res. 2012;2012: 872504.

[31] Volarevic V, Arsenijevic N, Lukic ML, et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells. 2011;29(1):5-10.

[32] Shen WC, Liang CJ, Wu VC, et al. Endothelial progenitor cells derived from Wharton's jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1α/IL-8 expression. Stem Cells Dev. 2013;22(9): 1408-1418.

[33] Whiteley J, Bielecki R, Li M, et al. An expanded population of CD34+ cells from frozen banked umbilical cord blood demonstrate tissue repair mechanisms of mesenchymal stromal cells and circulating angiogenic cells in an ischemic hind limb model. Stem Cell Rev. 2014;10(3):338-350.

[34] Chen DY, Wei HJ, Lin KJ, et al. Three-dimensional cell aggregates composed of HUVECs and cbMSCs for therapeutic neovascularization in a mouse model of hindlimb ischemia. Biomaterials. 2013;34(8):1995-2004.

[35] Kwon YW, Heo SC, Jeong GO, et al. Tumor necrosis factor-α-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim Biophys Acta. 2013;1832(12):2136-2144.

[36] Huang CC, Chen DY, Wei HJ, et al. Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs. Biomaterials. 2013;34(37):9441-9450.

[37] Wan J, Cai Q, Liu Y. Effect of intramuscular bone marrow-derived mesenchymal stem cell transplantation in the leg for treatment of diabetic foot ulcers in rats. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(12):1730-1736.

[38] Doan CC, Le TL, Hoang NS, et al. Differentiation of umbilical cord lining membrane-derived mesenchymal stem cells into endothelial-like cells. Iran Biomed J. 2014;18(2):67-75.

[39] 郝晓娟,朱旅云. 缺氧预处理脐带间充质干细胞诱导分化为内皮样细胞[J].中国组织工程研究,2013,17(45):7869-7876.

[40] Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006;108(12):3938-3944.

[41] Li XY, Zheng ZH, Li XY, et al. Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cells: response and correction of immunological anomalies Curr Pharm Des. 2013;19(27): 4893-4899.

[42] 樊明世,杨晓凤,吴雁翔,等.人脐带间充质干细胞移植改善糖尿病兔下肢缺血[J].中国组织工程研究与临床康复,2011,15(1):33-36.

[43] Afzal S, Lalani EN, Poulsom R, et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol. 1998;29(2):155-165.

[44] 李晓玲,朱旅云,宋光耀,等.脐带间充质干细胞移植治疗糖尿病下肢血管病变[J].中国组织工程研究,2014,18(23):3670-3675.

[45] 王广宇,朱旅云,马利成,等.干细胞移植治疗糖尿病足[J].中国组织工程研究,2013,17(1):173-180.

[46] 李晓玲,朱旅云,宋光耀,等.脐带间充质干细胞移植对1型糖尿病大鼠模型血糖及肾脏病变的影响研究[J].解放军医药杂志,2013, 25(7):31-34.

[47] Mathew SA, Rajendran S, Gupta PK, et al. Modulation of physical environment makes placental mesenchymal stromal cells suitable for therapy. Cell Biol Int. 2013;37(11):1197-1204.

[48] He MC, Li J, Zhao CH. Effect of hypoxia on mesenchymal stem cells - review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15(2):433-436.

[49] Deschepper M, Manassero M, Oudina K, et al. Proangiogenic and prosurvival functions of glucose in human mesenchymal stem cells upon transplantation. Stem Cells. 2013;31(3):526-535.

[50] Ikeda Y, Fukuda N, Wada M, et al. Development of angiogenic cell and gene therapy by transplantation of umbilical cord blood with vascular endothelial growth factor gene. Hypertens Res. 2004;27(2):119-128.

[51] Kwon YW, Heo SC, Jeong GO, et al. Tumor necrosis factor-α-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim Biophys Acta. 2013;1832(12):2136-2144.

[52] Mikroulis D, Papanas N, Maltezos E, et al. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol. 2007;5(3):195-209.

[53] Ripa RS, Wang Y, Jørgensen E, et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J. 2006;27(15):1785-1792.

[54] Kobulnik J, Kuliszewski MA, Stewart DJ, et al. Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. J Am Coll Cardiol. 2009;54(18):1735-1742.

[55] Ishii M, Shibata R, Numaguchi Y, et al. Enhanced angiogenesis by transplantation of mesenchymal stem cell sheet created by a novel magnetic tissue engineering method. Arterioscler Thromb Vasc Biol. 2011t;31(10):2210-2215.

[56] Thibeault S, Rautureau Y, Oubaha M, et al. S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. Mol Cell. 2010;39(3):468-476.

[57] Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2007;25(7):1737-1745.

[58] Lönne M, Lavrentieva A, Walter JG, et al. Analysis of oxygen-dependent cytokine expression in human mesenchymal stem cells derived from umbilical cord. Cell Tissue Res. 2013;353(1):117-122.

[59] Chen J, Liu Z, Hong MM, et al. Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells. PLoS One. 20146;9(12):e115316.

[60] Han YF, Sun TJ, Han YQ, et al. Preparation of microencapsulated VEGF gene-modified human umbilical cord mesenchymal stem cells and in vitro culture. Eur Rev Med Pharmacol Sci. 2013;17(2):217-223.

[61] Grelier A, Cras A, Balitrand N, et al. Toll-like receptor 3 regulates cord blood-derived endothelial cell function in vitro and in vivo. Angiogenesis. 2013;16(4):821-836.

[62] Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006;108(12):3938-3944.

[63] Schneider RK, Anraths J, Kramann R, et al. The role of biomaterials in the direction of mesenchymal stem cell properties and extracellular matrix remodelling in dermal tissue engineering. Biomaterials. 2010;31(31):7948-7959.

[64] Karow M, Popp T, Egea V, et al. Wnt signalling in mouse mesenchymal stem cells: impact on proliferation, invasion and MMP expression. J Cell Mol Med. 2009;13(8B): 2506-2520.

[65] Bertram H, Boeuf S, Wachters J, et al. Matrix metalloprotease inhibitors suppress initiation and progression of chondrogenic differentiation of mesenchymal stromal cells in vitro. Stem Cells Dev. 2009;18(6):881-892.

[66] Kachgal S, Putnam AJ. Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms. Angiogenesis. 2011;14(1):47-59.

[67] Ries C, Egea V, Karow M, et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood. 2007;109(9):4055-4063.

[68] Mannello F, Tonti GA, Bagnara GP, et al. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells. 2006; 24(3):475-481.

[69] HoWangYin KY, Loinard C, Bakker W, et al. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia. Stem Cells. 2014;32(1):231-243.

[70] Nakamura Y, Ishikawa H, Kawai K, et al. Enhanced wound healing by topical administration of mesenchymal stem cells transfected with stromal cell-derived factor-1. Biomaterials. 2013;34(37):9393-9400.

[71] Yang D, Sun S, Wang Z, et al. Stromal cell-derived factor-1 receptor CXCR4-overexpressing bone marrow mesenchymal stem cells accelerate wound healing by migrating into skin injury areas. Cell Reprogram. 2013;15(3):206-215.

[72] Wang GX, Hu L, Zhang Z, et al. Construction of an adenoviral expression vector carrying FLAG and hrGFP-1 genes and its expression in bone marrow mesenchymal stem cells. Genet Mol Res. 2014;13(1):1070-1078.

[73] Zhang G, Lan X, Yen TC, et al. Therapeutic gene expression in transduced mesenchymal stem cells can be monitored using a reporter gene. Nucl Med Biol. 2012;39(8):1243-1250.

[74] Liang W, Cai Q, Liu Y. Transfection of human vascular endothelial growth factor 165 gene into rat bone marrow mesenchymal stem cells in vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011;25(11):1383-1388.

[75] 李晓玲,朱旅云,宋光耀,等.腺病毒介导血管内皮生长因子转染脐带间充质干细胞的实验研究[J].解放军医药杂志,2014, 26(5): 5-9.

[76] Amin AH, Abd Elmageed ZY, Nair D, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010;90(7):985-996.

[77] 李玉玲,李红,胡明均,等.腺病毒装载人vegf-165基因转染的间充质干细胞对下肢缺血性坏死大鼠模型促血管新生的作用[J].中国实验血液学杂志, 2010,18(6):1568-1573.

[78] Hsieh JY, Wang HW, Chang SJ, et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One. 2013;8(8):e72604.

[79] Kang EJ, Lee YH, Kim MJ, et al. Transplantation of porcine umbilical cord matrix mesenchymal stem cells in a mouse model of Parkinson's disease. J Tissue Eng Regen Med. 2013;7(3):169-182.

[80] Zhou N, Wang QP, Jin XF, et al. Effect of human umbilici mesenchymal stromal cells implantation on the BDNF expression in diabetic foot rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013;44(6):931-934.

[81] Zhao QS, Xia N, Zhao N, et al. Localization of human mesenchymal stem cells from umbilical cord blood and their role in repair of diabetic foot ulcers in rats. Int J Biol Sci. 2013; 10(1):80-89.

[82] Wang H, Qiu X, Ni P, et al. Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats. Int J Mol Med. 2014;33(2):263-270.

[83] Liu L, Yu Y, Hou Y, et al. Human umbilical cord mesenchymal stem cells transplantation promotes cutaneous wound healing of severe burned rats. PLoS One. 2014;9(2):e88348.

[84] Han Y, Tao R, Han Y, et al. Microencapsulated VEGF gene-modified umbilical cord mesenchymal stromal cells promote the vascularization of tissue-engineered dermis: an experimental study. Cytotherapy. 2014;16(2):160-169.

[85] Sun TJ, Tao R, Han YQ, et al. Therapeutic potential of umbilical cord mesenchymal stem cells with Wnt/β-catenin signaling pathway pre-activated for the treatment of diabetic wounds. Eur Rev Med Pharmacol Sci. 2014;18(17):2460- 2464.

[86] Shrestha C, Zhao L, Chen K, et al. Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media. Int J Endocrinol. 2013;2013:592454.

[87] O'Loughlin A, Kulkarni M, Creane M, et al. Topical administration of allogeneic mesenchymal stromal cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer. Diabetes. 2013;62(7):2588-2594.

[88] Fong CY, Tam K, Cheyyatraivendran S, et al. Human Wharton's jelly stem cells and its conditioned medium enhance healing of excisional and diabetic wounds. J Cell Biochem. 2014;115(2):290-302.

[89] Li XY, Zheng ZH, Li XY, et al. Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cells: response and correction of immunological anomalies. Curr Pharm Des. 2013;19(27): 4893-4899.

[90] Bartel RL, Booth E, Cramer C, et al. From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's Ixmyelocel-T. Stem Cell Rev. 2013;9(3):373-383.